| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Setmelanotide is a novel investigational therapeutic agent that belongs to a class of drugs known as melanocortin-4 receptor (MC4R) agonists. It is designed to target and activate the MC4R, a receptor in the hypothalamus that plays a crucial role in regulating energy balance and appetite. Setmelanotide has been developed for the treatment of rare genetic disorders of obesity, including monogenic lipodystrophy and pro-opiomelanocortin (POMC) and leptin receptor (LEPR) deficiency.
Mechanism of Action: Setmelanotide works by binding to and activating the MC4R, which is part of the melanocortin system. This activation helps to reduce hunger and increase energy expenditure, leading to weight loss or control in patients with specific genetic obesity disorders. The drug has been shown to mimic the effects of naturally occurring melanocyte-stimulating hormones.
Indications: Setmelanotide has been granted orphan drug designation for the treatment of obesity associated with several genetic disorders, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It is also being investigated for other rare obesity conditions caused by defects in the MC4R pathway.
){kind=link}